In 2017, Food and Drug Administration (FDA) approved benznidazole for children suffering from Chagas, in the age group of 2 to 12 years. This is the first approved safe and effective therapeutic for Chagas in the U.S. FDA granted benznidazole priority review and orphan product designation, as it is a rare disease and there have been no approved drugs for its treatment in the U.S. This approval is expected to influence manufacturers to develop new drugs and biological products for the prevention and treatment of rare diseases. Some of the major players operating in the global chagas disease treatment market are F. Hoffmann-La Roche Ltd., KaloBios Pharmaceuticals, Inc., Johnson & Johnson, Bayer AG., and ELEA SACIF Laboratory.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/934
“The Sample consists of Table of Content, Research framework of the actual report & research methodology adopted for it”
Adoption of nitro derivative compound drugs associated with the host immune response, help prevent the disease and avoid parasite proliferation. Drugs used in the treatment of Chagas disease include benznidazole and nifurtimox, however, these are associated with serious side effects such as headaches, skin rashes, photosensitivity, chest pain, dizziness, nausea, insomnia, and jaundice. This poses as a restraining factor for growth of the market. No drug has developed so far, has been able to completely cure the disease. This, however, provides market players with lucrative opportunities by working towards development of effective drugs to treat Chagas.
American trypanosomiasis, also referred to as Chagas disease, is caused by the parasite Trypanosoma cruzi (T.cruzi), which is transmitted by the bite of triatomine bugs. T. cruzi can also be transmitted by food contaminated with the parasite, blood transfusion, transmission from infected mother to newborn during gestational period, organ transplant, and laboratory accidents. Symptoms associated with Chagas are not severe and often left undiagnosed. The parasites hide mainly in the heart and digestive muscles during the chronic phase of the disease. Years after the onset of the chronic infection, diseases such as heart diseases (30%), megacolon, and megaseophagus are caused. Chagas disease is one of the most neglected parasitic infections in the U.S., however, it is targeted by the Center for Disease Control and Prevention (CDC) for community health action.
According to Food and Drug Administration (FDA), in 2017, around 300,000 people are estimated to be affected by Chagas disease in the U.S. Furthermore, World Health Organization (WHO) stated that, around 6 million to 7 million people are expected to be affected by Chagas disease in 2017, worldwide. Vector control is the most useful method to prevent the spread of Chagas disease, especially used in Latin America. High incidence rate and easy transmission mode of the disease is expected to increase the demand for treatment of Chagas disease. Non availability of vaccines and biological treatments are expected to create high opportunity for the market players.
Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/934
Chagas Disease Treatment Market Taxonomy
By Distribution Channel: Hospital Pharmacy,Retail Pharmacy,.
By Region:North America,Europe,Asia Pacific,Latin America,Middle East,Africa,.